These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 447033)

  • 1. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
    Neal EA; Meffin PJ; Gregory PB; Blaschke TF
    Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
    Pond SM; Tong T; Benowitz NL; Jacob P
    Aust N Z J Med; 1980 Oct; 10(5):515-9. PubMed ID: 6937164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.
    Gugler R; Lain P; Azarnoff DL
    J Pharmacol Exp Ther; 1975 Dec; 195(3):416-23. PubMed ID: 1195128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxmetidine (SK&F 92994): pharmacokinetic study in patients with in patients with liver cirrhosis.
    Miglio F; Baraldini M; Serra S; Facchini A; Stefanini GF; Meliconi R; Gasbarrini G; Labo' G
    Int J Clin Pharmacol Res; 1985; 5(6):399-404. PubMed ID: 2869000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
    Lacroix C; Tranvouez JL; Phan Hoang T; Duwoos H; Lafont O
    Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent bioavailability and metabolism of salicylamide in dogs.
    Waschek JA; Rubin GM; Tozer TN; Fielding RM; Couet WR; Effeney DJ; Pond SM
    J Pharmacol Exp Ther; 1984 Jul; 230(1):89-93. PubMed ID: 6747835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
    Hamberg O; Vilstrup H
    Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin.
    Hamberg O
    Dan Med Bull; 1997 Jun; 44(3):225-41. PubMed ID: 9233544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strain-gauge plethysmographic measurement of the systemic bioavailability of oral nitroglycerin in liver cirrhosis].
    Sabba' C; Pugliese D; Carbone P; Altomare E; Portincasa P; Buonamico P; Stufano N; D'Ercole M; Palasciano G; Albano O
    Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1825-31. PubMed ID: 6422959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of L-arginine on the systemic, mesenteric, and hepatic circulation in patients with cirrhosis.
    Kakumitsu S; Shijo H; Yokoyama M; Kim T; Akiyoshi N; Ota K; Kubara K; Okumura M; Inoue K
    Hepatology; 1998 Feb; 27(2):377-82. PubMed ID: 9462634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired elimination of meperidine in patients with liver disease.
    McHorse TS; Klotz U; Wilkinson G; Schenker S
    Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
    [No Abstract]   [Full Text] [Related]  

  • 20. Fate of orally given isosorbide dinitrate in cirrhotic patients.
    Bogaert MG; Rosseel MT; Elewaut A
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):491-2. PubMed ID: 6500768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.